EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
Cancer patients receiving drugs to lower the risk of anaemia may be...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have undergone chemotherapy....
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a regular basis...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more likely to...
Published Sunday 29 November 2009
Number of Americans with diabetes expected to double by 2034
The number of people developing diabetes in the US is expected to...
Published Sunday 29 November 2009
H1N1 virus appears to increase asthma risk in children
Asthma is a significant risk factor in children who have contracted the...
Published Sunday 29 November 2009
New treatment could prevent thrombosis in PAD patients
Thrombosis is a common side effect in patients undergoing bypass surgery for...
Published Sunday 29 November 2009
More Medical News
Treatment for pulmonary arterial hypertension is developed
14 Sep 2009 - Posted by the Editorial Team
Blocking the effects of endothelin has led to a successful treatment of pulmonary arterial hypertension.
This is according to researchers at Zurich School of Medicine, Switzerland, who said that the discovery offers hope in terms of treating other chronic diseases.
Endothelin's receptors, ETA and ETB, were first discovered in the early 1990s, with the substance's role involving the constriction of blood vessels and the stimulation of cell growth.
While findings have suggested that endothelin antagonists will play an important role in treating pulmonary hypertension therapy in the future, there are still issues to be resolved.
These include whether drugs that block ETA alone will be more effective in treating pulmonary hypertension than medications that block both ETA and ETB, while it also needs to be determined if drugs can be combined with others such as vasodilators.
Pulmonary arterial hypertension is characterised by raised pressure in the pulmonary arteries, which carry blood from the heart to the lungs in order to pick up oxygen.
Login and visit the Hypertension Knowledge Centre
- Discovery could have implications for pulmonary hypertension treatment 27/10/09
- Hypertension can be caused by bread and cereals 08/10/09
- MS symptoms could be aided by hypertension treatment 18/08/09
- Resting blood pressure lowered by beetroot juice 08/08/09
- High blood pressure drug could prevent dementia 23/07/09
- Revatio 0.8 mg/ml solution for injection
... pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Revatio (oral) is indicated for treatment of patients with pulmonary arterial hypertension classified as WHO ... - CARDURA XL Tablets
Hypertension : Cardura XL is indicated for the treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. In patients inadequately controlled on single antihypertensive therapy, Cardura XL may be used in combination with a thiazide diuretic ... - TRANDATE tablets
Trandate Tablets are indicated for the treatment of: 1. Mild, moderate or severe hypertension 2. Hypertension in pregnancy 3. Angina pectoris with existing hypertension - TRANDATE injection
Trandate Injection is indicated for the treatment of:- 1. Severe hypertension, including severe hypertension of pregnancy, when rapid control of blood pressure is essential. 2. Anaesthesia when a hypotensive technique is indicated. 3. Hypertensive episodes following acute myocardial infarction - Thelin 100 mg film-coated tablets
Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease ... - REVATIO 20 mg film-coated tablets
Treatment of patients with pulmonary arterial hypertension classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease ...





